
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About
Atea Pharmaceuticals Inc (AVIR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AVIR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Year Target Price $7.5
Year Target Price $7.5
1 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Under performing |
1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.46% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 295.25M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 3 | Beta 0.18 | 52 Weeks Range 2.46 - 4.14 | Updated Date 06/30/2025 |
52 Weeks Range 2.46 - 4.14 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.77% | Return on Equity (TTM) -30.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -130025504 | Price to Sales(TTM) 1.9 |
Enterprise Value -130025504 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 58.97 | Enterprise Value to EBITDA -260.47 | Shares Outstanding 85579504 | Shares Floating 66231667 |
Shares Outstanding 85579504 | Shares Floating 66231667 | ||
Percent Insiders 11.79 | Percent Institutions 68.34 |
Analyst Ratings
Rating 2 | Target Price 7.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 1 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Atea Pharmaceuticals Inc
Company Overview
History and Background
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to address unmet medical needs for patients suffering from life-threatening viral diseases. Founded in 2014, Atea's initial focus was on developing direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV). Over time, the company has expanded its pipeline to include treatments for other viral infections.
Core Business Areas
- Antiviral Therapeutics Development: Focused on discovering, developing, and commercializing oral therapies for serious viral diseases.
Leadership and Structure
The leadership team includes the CEO, CSO, and other key executives. The organizational structure is typical for a biopharmaceutical company, with departments focusing on research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Bemnifosbuvir: An oral antiviral in development for the treatment of COVID-19. While there is no current market share for Bemnifosbuvir because it is still in development, the potential revenue depends on the successful completion of clinical trials and regulatory approval. Competitors include Pfizer (Paxlovid), Merck (Molnupiravir), and Gilead Sciences (Remdesivir).
Market Dynamics
Industry Overview
The antiviral therapeutics market is driven by the prevalence of viral infections and the need for effective treatments. The market is competitive, with several large pharmaceutical companies developing and marketing antiviral drugs.
Positioning
Atea aims to differentiate itself by developing oral antiviral therapies that are convenient and effective. Its success depends on the clinical trial results and regulatory approvals of its product candidates.
Total Addressable Market (TAM)
The TAM for COVID-19 therapeutics and other antiviral treatments is significant, estimated to be in the billions of dollars annually. Atea's potential market share depends on the success of its drug candidates and its ability to compete with established players in the market.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Focus on oral antiviral therapies
- Proprietary drug discovery platform
Weaknesses
- Reliance on clinical trial success
- Limited commercialization experience
- High cash burn rate
Opportunities
- Expanding market for antiviral therapies
- Potential for partnerships with larger pharmaceutical companies
- Acquisition targets
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
Competitive Landscape
Atea faces stiff competition from established pharmaceutical companies with greater resources and experience in developing and commercializing antiviral therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the company's pipeline development and progress in clinical trials.
Future Projections: Future growth depends on the successful development and commercialization of its product candidates, particularly Bemnifosbuvir.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Bemnifosbuvir and exploration of new antiviral targets.
Summary
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on antiviral therapies. The company's success hinges on the clinical trial results of its lead drug candidate, Bemnifosbuvir, for COVID-19. Atea faces intense competition from larger, more established pharmaceutical companies. Continued clinical development success, partnerships, and further investment will be crucial to long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, investor presentations, analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Financial data is based on publicly available information and may be subject to change. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Atea Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-10-30 | Founder, Chairman, CEO & President Dr. Jean-Pierre Sommadossi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://ateapharma.com |
Full time employees 56 | Website https://ateapharma.com |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.